Table 3.
The Pathway Express Results of Differentially Expressed Genes Involved in ≥5 Pathways.
| Gene Symbol | Gene Description | Fold Change in Expression | Number of Pathways Gene Involved in | Chromosome Location |
|---|---|---|---|---|
| MAPK1 | Mitogen-activated protein kinase 1 | -2.01 | 17 (4–8, 10, 17, 21, 22, 24, 26, 37, 39–42, 44) | 22q11.21 |
| PIK3CB | Phosphoinositide-3-kinase, catalytic, beta polypeptide | -2.05 | 16 (3, 4, 6, 9, 14, 16–18, 24, 26, 33, 39–42, 45) | 3q22.3 |
| PIK3R1 | Phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) | -2.13 | 16 (3, 4, 6, 9, 14, 16–18, 24, 26, 33, 39–42, 45) | 5q13.1 |
| PRKCB1 | Protein kinase C, beta 1 | -11.24 | 15 (3–5, 7, 8, 10, 16–19, 22, 28, 36, 39, 41) | 16p11.2 |
| AKT3 | v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) | -2.54 | 14 (4, 5, 9, 14, 18, 24, 26, 33, 35, 36, 39, 41, 42, 45) | 1q43–q44 |
| MAP2K1 | Mitogen-activated protein kinase kinase 1 | -4.17 | 12 (4–8, 10, 17, 22, 24, 26, 39, 41) | 15q22.1–q22.33 |
| MAPK9 | Mitogen-activated protein kinase 9 | -3.48 | 11 (4, 5, 8, 14, 15, 24, 26, 28, 35, 40, 41) | 5q35 |
| MAPK10 | Mitogen-activated protein kinase 10 | -2.28 | 11 (4, 5, 8, 14, 15, 24, 26, 28, 35, 40, 41) | 4q22.1–q23 |
| PRKACB | Protein kinase, cAMP-dependent, catalytic, beta | -2.55 | 11 (5, 7–10, 19, 20, 24, 28, 46, 48) | 1p36.1 |
| PPP3CA | Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform (calcineurin A alpha) | -4.13 | 11 (5, 7, 9, 17–19, 21, 28, 31, 33, 39) | 4q21–q24 |
| PPP3CB | Protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform (calcineurin A beta) | -3.65 | 10 (5, 7, 9, 17–19, 21, 28, 31, 33, 39) | 10q21–q22 |
| PRKX | Protein kinase, X-linked | 2.08 | 10 (5, 7, 8, 10, 19, 20, 24, 28, 46, 48) | Xp22.3 |
| PPP3R1 | Protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa, alpha isoform (calcineurin B, type I) | -3.05 | 10 (5, 7, 9, 17–19, 21, 28, 33, 39) | 2p15 |
| IKBKB | Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase beta | 2.75 | 9 (5, 9, 14, 15, 18, 24, 33, 35, 40) | 8p11.2 |
| JUN | v-jun sarcoma virus 17 oncogene homolog (avian) | 2.49 | 9 (4, 5, 8, 14, 15, 18, 26, 28, 33) | 1p32-p31 |
| PAK1 | p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) | -7.87 | 7 (4–6, 15, 17, 21, 33) | 11q13–q14 |
| TP53 | Tumor protein p53 (Li-Fraumeni syndrome) | 3.14 | 7 (5, 9, 26, 28, 29, 31, 38) | 17p13.1 |
| PLCB1 | Phospholipase C, beta 1 (phosphoinositide-specific) | -2.73 | 7 (3, 7, 8, , 10, 19, 22, 28) | 20p12 |
| CALM1 | Calmodulin 1 (phosphorylase kinase, delta) | -2.22 | 7 (3, 7, 8, 19, 20, 24, 29) | 14q24–q31 |
| PDGFRA | Platelet-derived growth factor receptor, alpha polypeptide | 5.76 | 7 (4–6, 10, 19, 26, 47) | 4q11–q13 |
| CALM3 | Calmodulin 3 (phosphorylase kinase, delta) | -2.31 | 7 (3, 7, 8, 19, 20, 24, 29) | 19q13.2–q13.3 |
| ITGB1 | Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | 2.26 | 6 (2, 4, 6, 11, 16, 21) | 10p11.2 |
| ITPR1 | Inositol 1,4,5-triphosphate receptor, type 1 | -8.62 | 6 (3, 7, 8, 10, 19, 22) | 3p26–p25 |
| ITPR2 | Inositol 1,4,5-triphosphate receptor, type 2 | 5.42 | 6 (3, 7, 8, 10, 19, 22) | 12p11 |
| ROCK1 | Rho-associated, coiled-coil containing protein kinase 1 | 2.42 | 6 (4, 6, 16, 21, 28, 44) | 18q11.1 |
| NFKBIA | Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | 2.17 | 6 (9, 14, 15, 18, 33, 35) | 14q13 |
| ROCK2 | Rho-associated, coiled-coil containing protein kinase 2 | -2.40 | 6 (4, 6, 16, 21, 28, 44) | 2p24 |
| CCND1 | Cyclin D1 | 3.77 | 5 (4, 26, 28, 38, 45) | 11q13 |
| CAMK2A | Calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha | -36.77 | 5 (7, 8, 19, 20, 28) | 5q33.1 |
| CAMK2B | Calcium/calmodulin-dependent protein kinase (CaM kinase) II beta | -8.77 | 5 (7, 8, 19, 20, 28) | 7p14.3-p14.1 |
| GNAI3 | Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 | 2.72 | 5 (10, 16, 21, 22, 36) | 3p21 |
| TGFB1 | Transforming growth factor, beta 1 (Camurati-Engelmann disease) | 2.32 | 5 (5, 26, 38, 44, 47) | 19q13.1 |
| ACTN1 | Actinin, alpha 1 | 2.26 | 5 (4, 6, 16, 36, 37) | 14q22–q24 |
| PAK2 | p21 (CDKN1A)-activated kinase 2 | 2.23 | 5 (4–6, 21, 33) | 3q29 |
| FOS v-fos FBJ murine osteosarcoma viral oncogene homolog | 5.10 | 5 (5, 14, 18, 26, 33) | 14q24.3 | |
| ACTN2 | Actinin, alpha 2 | -2.52 | 5 (4, 6, 16, 36, 37) | 1q42–q43 |
| MAP2K4 | Mitogen-activated protein kinase kinase 4 | -3.30 | 5 (5, 8, 14, 15, 41) | 17p11.2 |
| PLA2G6 | Phospholipase A2, group VI (cytosolic, calcium-independent) | -2.02 | 5 (5, 8, 2, 39, 41) | 22q13.1 |
| PTPN6 | Protein tyrosine phosphatase, nonreceptor type 6 | 2.21 | 5 (17, 18, 33, 37, 45) | 12p13 |
| FAS | Fas (TNF receptor superfamily, member 6) | 5.90 | 5 (5, 9, 13, 17, 47) | 10q24.1 |
| CCND2 | Cyclin D2 | 2.02 | 5 (4, 26, 28, 38, 45) | 12p13 |
| PLA2G12A | Phospholipase A2, group XIIA | 3.99 | 5 (5, 8, 22, 39, 41) | 4q25 |
| GNAS | GNAS complex locus | -4.93 | 5 (8, 10, 19, 22, 48) | 20q13.3 |
| GNAI1 | Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 | -2.25 | 5 (10, 16, 21, 22, 36) | 7q21 |
| CAMK2G | Calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma | -3.40 | 5 (7, 8, 19, 20, 28) | 10q22 |